Bipolar Research And Innovation Network - BRAIN
Launched by NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY · Sep 16, 2005
Trial Information
Current as of May 08, 2025
Recruiting
Keywords
ClinConnect Summary
The Bipolar Research And Innovation Network (BRAIN) trial is studying the different types of people who have bipolar disorder and are receiving care in psychiatric departments in Norway. The goal is to learn more about these patients, including those who may also have other health conditions alongside bipolar disorder. This information can help improve treatment and support for individuals living with this condition.
If you or a family member have been admitted to a psychiatric facility for bipolar disorder and can give written consent to participate, you may be eligible to join the study. Participants will be asked to share their experiences and information about their health while being fully supported by the research team. It’s important to know that this study is open to everyone, regardless of age or gender, as long as they can provide consent. By participating, individuals can contribute valuable insights that may help others with bipolar disorder in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All admitted patients giving written consent to participate in the study
- Exclusion Criteria:
- • Patients without competence for consent.
About Norwegian University Of Science And Technology
The Norwegian University of Science and Technology (NTNU) is a leading research institution dedicated to advancing knowledge and innovation in various scientific fields. Renowned for its commitment to interdisciplinary collaboration, NTNU plays a pivotal role in addressing global health challenges through rigorous clinical trials and research initiatives. The university's emphasis on cutting-edge technology and its strong partnerships with healthcare sectors position it as a key player in translational research, ensuring that findings contribute effectively to improving public health and patient care. With a focus on ethical standards and scientific integrity, NTNU is dedicated to fostering advancements that enhance the quality of life and health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Trondheim, , Norway
Patients applied
Trial Officials
Gunnar Morken, PhD MD
Principal Investigator
Norwegian University of Science and Technology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials